Impact of the introduction of a guideline on the targeted detection of hereditary haemochromatosis

Netherlands Journal of Medicine

Volumn 63, Issue 6, 2005, Pages 205-214

  Jacobs, E M G ^a   Meulendijks, C F M ^a   Elving, L ^a   van der Wilt, G J ^a   Swinkels, D W ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Genetic testing; Guideline adherence; Haemochromatosis; Practice guideline; Serum iron measurements

Indexed keywords

FERRITIN; HFE PROTEIN; IRON; TRANSFERRIN;

ADULT; ARTICLE; CONTINUING EDUCATION; CONTROLLED STUDY; DATA ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; EARLY DIAGNOSIS; FEMALE; FERRITIN BLOOD LEVEL; GENE MUTATION; GENOTYPE; HEALTH CARE COST; HEMOCHROMATOSIS; HOSPITAL DISCHARGE; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; OUTPATIENT DEPARTMENT; PRACTICE GUIDELINE; RETROSPECTIVE STUDY; TRANSFERRIN BLOOD LEVEL;

BIOPSY; COSTS AND COST ANALYSIS; FEMALE; FERRITINS; GENETIC SCREENING; GENOTYPE; GUIDELINE ADHERENCE; HEMOCHROMATOSIS; HUMANS; LIVER; MALE; MIDDLE AGED; MUTATION; PATIENT SELECTION; PRACTICE GUIDELINES; RETROSPECTIVE STUDIES; TRANSFERRIN;

EID: 21344454916     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Feder JN, Gnirke A, Thomas W, et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 1996;13(4):399-408.
2. Bacon BR, Powell LW, Adams PC, Kresina TF, Hoofnagle JH. Molecular medicine and hemochromatosis: at the crossroads. Gastroenterology 1999;116(1):193-207.
3. Hanson EH, Imperatore G, Burke W. HFE gene and hereditary hemochromatosis: a HuGE review. Human Genome Epidemiology. Am J Epidemiol 2001;154(3):193-206.
4. Bacon BR. Hemochromatosis: diagnosis and management. Gastroenterology 2001;120(3):718-25.
5. Adams P, Brissot P, Powell LW. EASL International Consensus Conference on Haemochromatosis. J Hepatol 2000;33(3):485-504.
6. Niederau C, Fischer R, Purschel A, Stremmel W, Haussinger D, Strohmeyer G. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology 1996;110(4):1107-19.
7. Yang Q, McDonnell SM, Khoury MJ, Cono J, Parrish RG. Hemochromatosis-associated mortality in the United States from 1979 to 1992: an analysis of Multiple-Cause Mortality Data. Ann Intern Med 1998;129(11):946-53.
8. Adams PC, Deugnier Y, Moirand R, Brissot P. The relationship between iron overload, clinical symptoms, and age in 410 patients with genetic hemochromatosis. Hepatology 1997;25(1)162-6.
9. Distante S, Berg JP, Lande K, Haug E, Bell H. HFE gene mutation (C282Y) and phenotypic expression among a hospitalised population in a high prevalence area of haemochromatosis. Gut 2000;47(4):575-9.
10. Pietrangelo A. Hereditary hemochromatosis - a new look at an old disease. N Engl J Med 2004;350(23):2383-97.
11. Barton JC, McDonnell SM, Adams PC, et al. Management of hemochromatosis. Hemochromatosis Management Working Group. Ann Intern Med 1998;129(11):932-9.
12. Wojcik JP, Speechley MR, Kertesz AE, Chakrabarti S, Adams PC. Natural history of C282Y homozygotes For hemochromatosis. Can J Gastroenterol 2002;16(5):297-302.
13. Emery J, Hayflick S. The challenge of integrating genetic medicine into primary care. BMJ 2001;322(7293):1027-30.
14. Phatak PD, Guzman G, Woll JE, Robeson A, Phelps CE. Cost-effectiveness of screening for hereditary hemochromatosis. Arch Intern Med 1994;154(7):769-76.
15. Adams PC, Gregor JC, Kertesz AE, Valberg LS. Screening blood donors for hereditary hemochromatosis: decision analysis model based on a 30-year database. Gastroenterology 1995;109(1):177-88.
16. Adams PC, Kertesz AE, Valberg LS. Clinical presentation of hemochromatosis: a changing scene. Am J Med 1991;90(4):445-9.
17. Brissot P, Moirand R, Guyader D, Loreal O, Turlin B, Deugnier Y. Hemochromatosis after the gene discovery: revisiting the diagnostic strategy. J Hepatol 1998;28(suppl 1):14-8.
18. Bulaj ZJ, Griffen LM, Jorde LB, Edwards CQ, Kushner JP. Clinical and biochemical abnormalities in people heterozygous For hemochromatosis. N Engl J Med 1996;335(24):1799-1805.
19. Guyader D, Jacquelinet C, Moirand R, et al. Noninvasive prediction of fibrosis in C282Y homozygous hemochromatosis. Gastroenterology 1998;115(4):929-36.
20. Powell LW, Summers KM, Board PG, Axelsen E, Webb S, Halliday JW. Expression of hemochromatosis in homozygous subjects. Implications For early diagnosis and prevention. Gastroenterology 1990;98(6):1625-32.
21. Brother E. Commission on Professional and Hospital Activities, International Classification of Diseases, 9th rev. ed. Clinical modification. 1978.
22. CTG tariffs 2003, Bijlage tariefbeschikking 5699-3000-03-02.2003.
23. Swinkels DW, Marx JJ. [Diagnosis and treatment of primary hemochromatosis]. Ned Tijdschr Geneeskd 1999;143(27):1404-8.
24. Andersen RV, Tybjaerg-Hansen A, Appleyard M, Birgens H, Nordestgaard BG. Hemochromatosis mutations in the general population: iron overload progression rate. Blood 2004;103(8):2914-9.
25. Beutler E. Genetic irony beyond haemochromatosis: clinical effects of HLA-H mutations. Lancet 1997;349(9048):296-7.
26. Adams PC. Population screening for hemochromatosis. Hepatology 1999;2-9(4);1324-7.
27. Adams PC, Kertesz AE, McLaren CE, Barr R, Bamford A, Chakrabarti S. Population screening for hemochromatosis: a comparison of unbound iron-binding capacity, transferrin saturation, and C282Y genotyping in 5,211 voluntary blood donors. Hepatology 2000;31(5):1160-4.
28. Beutler E, Felitti V, Gelbart T, Ho N. The effect of HFE genotypes on measurements of iron overload in patients attending a health appraisal clinic. Ann Intern Med 2000;133(5):329-37.
29. Beutler E, Felitti VJ, Koziol JA, Ho NJ, Gelbart T. Penetrance of 845G →A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet 2002;359(9302):211-8.
30. Cox T, Rochette J, Camaschella C, Walkera A, Robson K. Clinical haemochromatosis in HFE mutation carriers. Lancet 2002;360:412.
31. Mura C, Le Gac G, Scotet V, Raguenes O, Mercier AY, Ferec C. Variation of iron loading expression in C282Y homozygous haemochromatosis probands and sib pairs. J Med Genet 2001;38(9):632-6.
32. Sham RL, Raubertas RF, Braggins C, Cappuccio J, Gallagher M, Phatak PD. Asymptomatic hemochromatosis subjects: genotypic and phenotypic profiles. Blood 2000;96(12):3707-11.
33. Powell LW. Diagnosis of hemochromatosis. Semin Gastrointest Dis 2002;13(2);80-8.
34. Powell LW, Dixon JL, Hewett DG. Role of early case detection by screening relatives of patients with HFE-associated hereditary haemochromatosis. Best Pract Res Clin Haematol 2005;18(2):221-34.
35. Cadet E, Capron D, Perez AS, et al. A targeted approach significantly increases the identification rate of patients with undiagnosed haemochromatosis. J Intern Med 2003;253(2):217-24.
36. Olsson KS, Eriksson K, Ritter B, Heedman PA. Screening For iron overload using transferrin saturation. Acta Med Scand 1984;215(2):105-12.
37. Leggett BA, Halliday JW, Brown NN, Bryant S, Powell LW. Prevalence of haemochromatosis amongst asymptomatic Australians. Br J Haematol 1990;74(4):525-30.
38. Cabana MD, Rand CS, Powe NR, et al. Why don't physicians follow clinical practice guidelines? A framework for improvement. JAMA 1999;282(15):1458-65.
39. Van Wilk MA, van der Lei J, Mosseveld M, Bohnen AM, van Bemmel JH. Compliance of general practitioners with a guideline-based decision support system for ordering blood tests. Clin Chem 2002;48(1):55-60.
40. Maue SK, Segal R, Kimberlin CL, Lipowski EE. Predicting physician guideline compliance: an assessment of motivators and perceived barriers. Am J Manag Care 2004;10(6):383-91.